Terms ending in 2030
Every in-force patent on Adamas Pharma, LLC's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,741,343 | Method of Administering Amantadine Prior to a Sleep Period In force · High confidence | Adamas Pharma, LLC | In force | High confidence | |
| US 9,867,791 | Method of administering amantadine prior to a sleep period In force · High confidence | Adamas Pharma, LLC | In force | High confidence | |
| US 9,867,792 | Method of administering amantadine prior to a sleep period In force · Medium confidence | Adamas Pharma, LLC | In force | Medium confidence | |
| US 9,867,793 | Method of administering amantadine prior to a sleep period In force · High confidence | Adamas Pharma, LLC | In force | High confidence | |
| US 9,877,933 | Method of administering amantadine prior to a sleep period In force · High confidence | Adamas Pharma, LLC | In force | High confidence | |
| US 11,197,835 | Method of administering amantadine prior to a sleep period In force · Medium confidence | Adamas Pharma, LLC | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.